Ann: Change of Director's Interest Notice - R, page-11

re: Ann: Change of Director's Interest No... "Straight comparisons like that aren't enough, there's a lot more behind the scenes such as management ability, marketability of the company and it's products, track record for delivery, product risk profile, etc"

Spot on Wilson how many biotechs can show this sought of pedigree on their board and in their top 20 shareholders....

Robert (Bob) Moses was formerly Corporate Vice President of CSL Limited. Mr. Moses draws on more than 40 years’ experience in the pharmaceutical/biotechnology industry. During the period 1993-2001, Mr. Moses played a central role in CSL’s development internationally. Prior to joining CSL, Mr. Moses was Managing Director of commercial law firm Freehills, Chairman and CEO of a NASDAQ listed medical service company, and Corporate Manager of New Business Development at ICI (now Orica). Mr. Moses is also the former Non-Executive Chairman of TGR Biosciences Pty Ltd. Mr. Moses also spent 17 years in various management roles at the multinational pharmaceutical company Eli Lilly.

He took Csl from a flagging government owned business to an independant thriving global enterprise. The share price over that time went from 75c to over $17.00.
Lost on many but Robert commands a huge amount of respect in the biotech industry and quite simply, guys like this rarely lend their credibility. Yet here he is as our Chairman and a major shareholder who continues to buy.
One of the many reasons that made anp attractive to me anyway.